X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1332) 1332
index medicus (834) 834
oncology (793) 793
male (782) 782
female (765) 765
middle aged (694) 694
adult (637) 637
hematology (601) 601
aged (567) 567
aggressive lymphoma (470) 470
non-hodgkins-lymphoma (465) 465
chemotherapy (420) 420
prognosis (408) 408
antineoplastic combined chemotherapy protocols - therapeutic use (402) 402
cancer (366) 366
treatment outcome (347) 347
lymphomas (288) 288
adolescent (270) 270
rituximab (269) 269
elderly-patients (263) 263
aged, 80 and over (234) 234
lymphoma (217) 217
cyclophosphamide - administration & dosage (214) 214
retrospective studies (210) 210
aggressive lymphomas (205) 205
lymphoma, large b-cell, diffuse - drug therapy (200) 200
disease-free survival (188) 188
care and treatment (187) 187
antineoplastic combined chemotherapy protocols - administration & dosage (186) 186
doxorubicin - administration & dosage (186) 186
vincristine - administration & dosage (185) 185
lymphoma, non-hodgkin - drug therapy (184) 184
pathology (177) 177
survival analysis (172) 172
young adult (169) 169
prednisone - administration & dosage (167) 167
transplantation (167) 167
tumors (167) 167
survival (155) 155
survival rate (149) 149
b-cell lymphoma (146) 146
medicine & public health (146) 146
analysis (144) 144
combined modality therapy (140) 140
therapy (140) 140
neoplasm staging (139) 139
aggressive behavior (138) 138
risk factors (137) 137
lymphoma, large b-cell, diffuse - pathology (136) 136
high-dose chemotherapy (134) 134
bone-marrow-transplantation (132) 132
expression (132) 132
recurrence (131) 131
research (123) 123
diagnosis (120) 120
immunohistochemistry (118) 118
positron-emission-tomography (118) 118
diffuse large b-cell lymphoma (117) 117
follow-up studies (115) 115
disease (112) 112
lymphoma, large b-cell, diffuse - mortality (111) 111
antineoplastic combined chemotherapy protocols - adverse effects (109) 109
3-weekly chop chemotherapy (108) 108
leukemia (107) 107
remission induction (106) 106
malignant-lymphoma (105) 105
non-hodgkin's lymphomas (105) 105
antineoplastic agents - therapeutic use (104) 104
lymphoma, non-hodgkin - pathology (101) 101
transplantation, autologous (100) 100
chop (99) 99
hemic and lymphatic diseases (99) 99
trial (96) 96
phase-ii (95) 95
surgery (95) 95
animals (94) 94
cyclophosphamide - therapeutic use (94) 94
etoposide - administration & dosage (94) 94
health aspects (94) 94
lymphoma, large b-cell, diffuse - therapy (94) 94
radiotherapy (94) 94
lymphoma, non-hodgkin - mortality (93) 93
hematology, oncology and palliative medicine (92) 92
stem cells (92) 92
fdg-pet (91) 91
genetic aspects (90) 90
lymphoma, non-hodgkin - therapy (90) 90
classification (89) 89
radiology, nuclear medicine & medical imaging (87) 87
aggressive variants (86) 86
antibodies, monoclonal, murine-derived (85) 85
bone-marrow transplantation (83) 83
chemotherapy plus rituximab (83) 83
vincristine - therapeutic use (83) 83
follicular lymphoma (82) 82
gene expression (82) 82
immunology (82) 82
cyclophosphamide (80) 80
doxorubicin - therapeutic use (80) 80
prednisone - therapeutic use (80) 80
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1814) 1814
French (25) 25
German (19) 19
Spanish (10) 10
Russian (6) 6
Korean (5) 5
Polish (3) 3
Japanese (2) 2
Chinese (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2014, Volume 89, Issue 5, pp. 536 - 541
Increasing dose intensity (DI) of chemotherapy for patients with aggressive non‐Hodgkin lymphoma (NHL) may improve outcomes at the cost of increased toxicity.... 
B-CELL LYMPHOMA | EPIRUBICIN | 3-WEEKLY CHOP CHEMOTHERAPY | AGGRESSIVE LYMPHOMAS | INTENSITY | NON-HODGKINS-LYMPHOMA | YOUNG-PATIENTS | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Epirubicin - administration & dosage | Recombinant Proteins - adverse effects | Cyclophosphamide - adverse effects | Filgrastim | Young Adult | Vincristine - administration & dosage | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Granulocyte Colony-Stimulating Factor - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Recombinant Proteins - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - adverse effects | Aged | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Anthracyclines | Chemotherapy | Biological products | Corticosteroids | Granulocyte colony-stimulating factor | Leukemia | Lymphomas | Product development | Dosage and administration | Standards | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 04/2015, Volume 121, Issue 7, pp. 1032 - 1039
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 18, pp. 3418 - 3425
Journal Article